* Adamis Pharmaceuticals Corp ADMP.OQ ADMP.O is expected
to show a fall in quarterly revenue when it reports results on
March 31.
* The San Diego California-based company is expected to
report a
22.5% decrease in revenue to $2.818 million from $3.64 million a
year ago, according to the mean estimate from 2 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for Adamis
Pharmaceuticals
Corp is for a loss of 4 cents per share. For the same quarter
last year, the company reported a loss of 24 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
This summary was machine generated March 29 at 21:06 GMT. All
figures in US dollars unless otherwise stated